Compare Cassava Sciences Inc (FLNA) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Paycom Software Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Paycom Software Inc trades at $149.75 (market cap $6.75B). The key difference: Paycom Software Inc is far larger — about 127× Cassava Sciences Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PAYC | |
|---|---|---|
Market Cap | $53.14M | $6.75B |
Sector | Health | Technology |
52-Week High | $4.64 | $238.80 |
52-Week Low | $1.09 | $113.59 |
Enterprise Value | -$33.43M | $7.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Paycom Software (PAYC) trades at $152.79, up 6.35% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $151.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, with revenue growing to $2.05 billion in 2025. The company maintains strong profitability, including a 22.44% net income margin and 37.15% ROE, while launching new tools like Asset Management to drive growth.
Outlook is cautiously optimistic, with potential upside to the $183.00 high target, supported by solid fundamentals and product innovation. Risks include competitive pressures in HCM software and reliance on steady revenue growth. Investors should weigh the stock's current valuation against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
